Incyte Forecasts 2024 Jakafi Net Product Revenue Of $2.71B-$2.75B Versus Prior Guidance Of $2.69B-$2.75B
Portfolio Pulse from Benzinga Newsdesk
Incyte has updated its 2024 financial guidance, raising the lower end of its Jakafi net product revenue forecast to $2.71B-$2.75B from the previous $2.69B-$2.75B. The company also updated its R&D expenses due to the acquisition of Escient Pharmaceuticals, while maintaining other revenue and expense guidance.
July 30, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incyte has raised the lower end of its 2024 Jakafi revenue guidance to $2.71B-$2.75B and updated its R&D expenses due to the acquisition of Escient Pharmaceuticals. Other financial guidance remains unchanged.
The increase in the lower end of Jakafi revenue guidance indicates stronger expected performance, which is positive for Incyte's stock. The update in R&D expenses reflects the impact of the recent acquisition, which could lead to future growth opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100